Vivaldi Biosciences, Inc.
PrivateLast Round
Grant
Dec 18, 2023
Total Funding Raised
$33.64M
Company Overview
Vivaldi Biosciences, Inc. operates in Healthcare & Life Sciences and is based in Fort Collins, Colorado. Its latest recorded funding round was a Grant round in December 2023.
Vivaldi Biosciences, Inc. is a biotechnology company that develops intranasal vaccines for the protection against respiratory diseases using its proprietary Delta NS1 technology platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivaldi Biosciences, Inc. Comparables
Compare Vivaldi Biosciences, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Codagenix | 85% | |
| FluGen, Inc. | 84% | |
| Osivax | 82% |
For institutional investors. Book with your work email.
Vivaldi Biosciences, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 18, 2023 | ||||
| Grant | Jun 5, 2023 | ||||
| Series A | Jan 8, 2009 | ||||
| Debt | May 18, 2007 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vivaldi Biosciences, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bay City Capital | Debt, Series A |
| Flu Lab | Grant |
| NGN Capital | Series A |
| European Union | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 6, 2026
Monthly visitors increased 49% MoM.
- Nov 19, 2025
US patent awarded for universal influenza vaccine using DelNS1 technology.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 2, 2026
Vivaldi Biosciences Inc. is developing DelNS1 H5N1, a candidate intended to protect against avian influenza A(H5N1); its vaccine candidates are designed to generate immune responses in the upper respiratory tract without replicating or producing viral offspring.
- is_developingSep 2, 2026
Vivaldi Biosciences Inc. is developing DeltaFLU, an influenza vaccine candidate.
For institutional investors. Book with your work email.
Vivaldi Biosciences, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vivaldi Biosciences, Inc.'s valuation, stock price, and market status.
Is Vivaldi Biosciences, Inc. a public or private company?
Vivaldi Biosciences, Inc. is a private company.
What is the current stock price of Vivaldi Biosciences, Inc.?
Vivaldi Biosciences, Inc. is a private company, so its shares have no public market price. Caplight tracks Vivaldi Biosciences, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vivaldi Biosciences, Inc. worth (valuation)?
Valuation information for Vivaldi Biosciences, Inc. is not publicly available.
Can I buy Vivaldi Biosciences, Inc. stock?
Vivaldi Biosciences, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vivaldi Biosciences, Inc.'s last funding round?
Vivaldi Biosciences, Inc.'s most recent funding round was Grant on December 18, 2023.
Who are the main investors in Vivaldi Biosciences, Inc.?
Key investors in Vivaldi Biosciences, Inc. include Bay City Capital, NGN Capital, European Union.
Will Vivaldi Biosciences, Inc. IPO soon?
No public IPO plans have been announced for Vivaldi Biosciences, Inc..
How can I track Vivaldi Biosciences, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Vivaldi Biosciences, Inc.'s shares on secondary markets.